Orexo AB (CHIX:ORXS) FFO


CHIX:ORXS Orexo AB CHIX:ORXS
47 GF Score
Price kr30.95
GF Value kr9.54
! 7 Warning Signs
View Full Analysis

What is Orexo AB FFO?

FFO (Funds from operations) only applies to REITs.

CHIX:ORXS
47GF Score
Orexo AB CHIX:ORXS
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Orexo AB (CHIX:ORXS) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of kr30.95 is trading 224.4% above its estimated GF Value™ of kr9.54.

Key valuation signals for CHIX:ORXS:

  • FFO:
  • GF Value™: kr9.54 vs. price of kr30.95 (224.4% above fair value)
  • GF Score™: 47/100 with 7 warning signs

No single metric tells the full story. See the CHIX:ORXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
47GF Score

Get the complete analysis for CHIX:ORXS

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr30.95
Price
kr9.54
GF Value